The core purpose of Акридерм (Betamethasone Dipropionate) is to provide symptomatic relief for the inflammatory and pruritic manifestations of a variety of skin diseases. It is primarily used when symptoms are pronounced and disrupt a patient’s daily comfort. This class of medication may be part of symptomatic management for conditions involving inflammatory or irritative processes that are typically corticosteroid-responsive.

It is commonly applied across conditions like psoriasis, various forms of eczema and dermatitis (such as atopic eczema and contact dermatitis), lichen planus, and localized forms of discoid lupus erythematosus. It helps address symptom clusters that may become intense or disruptive, providing support to stabilize the affected skin area.

It plays a role in managing intense skin inflammation and associated persistent itching (pruritus). When symptoms become temporarily overwhelming, Акридерм may assist with easing the accompanying redness and swelling. This supportive therapeutic benefit contributes to easing the overall symptom load and assists patients in coping more steadily with difficult, acute episodes.

---

Quick Fact: Relief for Intense Pruritus The medication is relevant for easing pronounced itching associated with chronic skin conditions, and may assist with managing symptoms that create noticeable physiological strain and supports the patient during difficult symptomatic periods.

Regulatory References

1. NIH DailyMed overview

This section outlines the official population-based restrictions for the use of Акридерм (a topical corticosteroid containing betamethasone), as defined in regulatory documentation.

---

Eligibility scope

Population Category	Eligibility Status (Official)
Use Allowed	Adults and children from 1 year of age for approved indications.
Contraindicated	Patients with known hypersensitivity to betamethasone or any component.
Contraindicated	Patients with viral skin infections (e.g., herpes simplex, chickenpox), skin tuberculosis, or syphilis manifestations.
Contraindicated	Children under 1 year of age.
Restricted Use	Use in pregnancy or lactation is contraindicated on large skin areas or for prolonged periods.
Restricted Use	Should be avoided on the face, groin, armpits, or where skin integrity is compromised (e.g., open wounds, trophic ulcers).

---

Eligibility classifications (high-level)

The regulatory profile defines eligibility through absolute contraindications for specific infectious diseases and a minimum age limit of one year. The drug's classification as a potent corticosteroid necessitates restricted use for physiological states like pregnancy and on sensitive anatomical sites to mitigate systemic absorption risk. These statements strictly define the population ineligible for treatment under normal circumstances.

Interaction Map: Interactions with other medicines and products — official regulatory information for Акридерм (Betamethasone Dipropionate Topical)

---

Interaction scope

• Medicinal product categories with documented interactions: Other Corticosteroid-Containing Products (topical or systemic).
• Specific interacting medicines (if explicitly listed): None explicitly named by compound (only the category is listed).
• Mechanistic basis of interactions (only if stated in label): Additive systemic exposure due to the cumulative glucocorticoid effect from co-administration. Also, augmented percutaneous absorption when used with occlusive dressings.
• Timing-based interaction rules (if applicable): None are explicitly detailed for co-administered medicinal products.
• Population-specific interaction notes (if applicable): Pediatric patients are identified as having a greater susceptibility to systemic toxicity resulting from augmented systemic exposure. Patients with liver failure are noted to have increased risk of systemic effects due to potential decreased clearance of absorbed substance.
• Interaction-related restrictions: The official label advises against the concomitant use of Акридерм with other corticosteroid-containing products.

---

Interaction classifications (high-level)

• Interaction severity classification (as defined in official documents): Clinically significant interaction risk (Additive systemic glucocorticoid exposure leading to potential HPA axis suppression).
• Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information / DailyMed.
• Interaction-context constraints (as defined in official documents): The risk of cumulative systemic exposure is substantially augmented by the use of occlusive dressings or application over large surface areas or for prolonged periods.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with other corticosteroid-containing products may result in an increase in total systemic glucocorticoid exposure.
• The use of occlusive dressings with this product is documented to augment percutaneous absorption, which elevates the risk of systemic effects.
• The official label includes a specific restriction advising against the use of other corticosteroid-containing products concurrently with this medicine.
• Pediatric patients are formally identified as a population with heightened susceptibility to systemic toxicity stemming from augmented absorption and subsequent interaction effects.

Connection to the overall interaction profile (4 sentences): The official regulatory interaction profile for Акридерм is defined by the risk of an additive pharmacodynamic effect involving cumulative systemic glucocorticoid exposure. The primary documented interaction is the effect of co-administered other corticosteroid-containing products, which is noted as a restriction in the label. The profile also includes the documented exposure-modifying effect of using occlusive dressings, which increases the amount of medicine absorbed into the body. This structure confirms that the official interaction concerns are centered on managing the risk of cumulative glucocorticoid load from all sources, as explicitly stated in government documents.

Core Action: Modulating Gene Expression via Receptor Agonism

The primary mechanism of Betamethasone Dipropionate begins when the molecule acts as an agonist at the intracellular Glucocorticoid Receptor (GR). This activated complex then translocates to the cell nucleus to modulate genetic activity. The drug works by genomic transrepression, directly interfering with the ability of key pro-inflammatory transcription factors, such as NF-kappaB, to synthesize messengers that fuel the inflammatory cascade.

---

Suppression of Inflammatory Mediator Production

This genomic action directly suppresses the Arachidonic Acid Cascade. The mechanism induces the synthesis of the protein Lipocortin-1, which subsequently inhibits the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the drug halts the release of the precursor needed to produce inflammatory mediators like prostaglandins and leukotrienes. This upstream intervention results in a reduction in localized inflammatory signaling.

---

Physiological Consequence: Vascular and Cellular Stabilization

The overall result of the molecular cascade is a broad modulation of the local tissue response. The mechanism causes immediate localized vasoconstriction and suppresses the synthesis of signals (chemokines) that attract immune cells. These effects result in physiological adjustments, specifically a reduction of blood flow and suppression of vascular permeability at the site of application.

Official Administration Principles

The use of Акридерм (Betamethasone Dipropionate topical preparation) is governed by procedural constraints established in standard clinical protocols, defining its application as a short-term, site-specific regimen.

Administration Route and Frequency

The medicine is designated solely for topical or cutaneous application and is explicitly not for oral, ophthalmic, or internal use. The product is available as a cream, ointment, or lotion at the 0.05% strength. The standard schedule for application is typically once daily or, in some cases, twice daily.

Application Rules and Limits

The standard procedure is to apply a thin film to the affected skin area and rub it in gently. For liquid forms, such as the lotion or spray, the product must be shaken well before using to ensure uniform consistency.

Standard parameters include strict limits on usage quantity and duration. Continuous application is restricted to a maximum of 2 consecutive weeks for certain augmented formulations, and treatment is generally discontinued when control is achieved. A critical mandate is that the total quantity used must not exceed 50 grams or 50 mL per week.

Constraints on Use

Procedural constraints dictate that the treated area must not be covered with occlusive dressings or bandaging unless directed. Application is also strictly avoided on sensitive body areas including the face, groin, and underarms. Regarding age, the use of this potent formulation is not recommended for children 12 years of age and younger, with application being reserved for patients 13 years of age and older.

Research evidence / Overview of Studies for Акридерм

---

Evidence for Use in Psoriasis Vulgaris (Plaque Psoriasis)

Research applied to the active ingredient in Акридерм for psoriasis is derived primarily from Randomized Controlled Trials (RCTs). These studies were applied in research exploring how symptoms change over time, which is typical of plaque psoriasis. Researchers examined the medicine in adults and adolescents with established diagnoses. The studies explored how symptoms are measured using standardized assessment tools like the Psoriasis Area and Severity Index (PASI) and the Investigator's Global Assessment (IGA), which monitor physiological strain linked to inflammatory states.

The findings from these trials describe patterns observed in the studied populations over defined time intervals. Research monitored changes measured during short-term and intermediate-term observation periods. However, key limitations exist: the results apply only to the populations studied, and certainty remains low for outcomes beyond a few weeks. The follow-up durations were limited, meaning long-term effects are not fully established.

---

Evidence for Use in Other Inflammatory Skin Conditions

Research has also examined the active ingredient in Акридерм for other conditions characterized by fluctuating or episodic manifestations, such as eczema, dermatitis, and lichen planus. Studies explored outcomes linked to inflammatory states, focusing on symptoms like redness and patient-reported outcomes describing perceived discomfort (itching).

Key limitations exist in the evidence base for these broader inflammatory conditions, often relying on smaller studies. The evidence quality varies across studies, and many conclusions may be informed by research on the broader class of potent topical steroids, meaning data on the active ingredient alone across all these indications is heavily informed by class data.

---

Understanding the Strength and Gaps in Evidence

The research landscape for Акридерм comprises studies for its primary indications but is not without limitations. The initial treatment response trials typically monitored responses over defined time intervals of four to eight weeks, leading to limited information for long-term outcomes related to continuous or intermittent use. Research evaluated the active ingredient in pediatric populations, but data for certain groups remain insufficient. While studies help show what has been observed so far, the findings describe group patterns, not personal outcomes.

Key Studies & References

1. DailyMed: Label and Regulatory Information for Betamethasone Dipropionate Ointment (Focus on clinical studies and indications)

Common questions about Акридерм (FAQ)

Q: What should I do if my child accidentally swallowed the Акридерм cream?

Regulatory documents indicate that accidental oral ingestion (swallowing) of the topical cream, due to its low steroid content, is unlikely to produce toxic effects. Official safety information includes the standard requirement to keep the product out of the sight and reach of children to prevent accidental ingestion.

Q: Can I use Акридерм with my regular skin care products like moisturizer or toner?

Official product information primarily focuses on avoiding co-administration with other corticosteroid-containing products to mitigate the risk of cumulative steroid exposure. This guidance emphasizes that the main safety concern is related to other medicinal products. The question of using non-medicinal topical products, such as moisturizers or toners, is not typically addressed in the specific interaction statements for this medicine.

How to Store and Dispose of Acriderm (Betamethasone Dipropionate)

Official regulatory documents specify mandatory conditions for the storage and disposal of Acriderm to maintain its stability and effectiveness.

Storage Requirements

Condition	Official Requirement
Temperature	Store at controlled room temperature, below 25°C (77°F).
Protection	Keep the product in its original container, tightly closed.
Prohibition	Do not freeze the medicine.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Acriderm must be disposed of according to local pharmaceutical waste regulations. The medicine should not be flushed down a toilet or poured into a drain, as required by environmental protection guidelines for medicinal products. Consult local authorities or a pharmacist for the proper disposal method.